Glucotrack settles Alto debt dispute with $2M cash and $2M convertible note

Glucotrack, Inc.

Settlement with Alto resolves ~$10.9M asserted debt from Apimeds Pharmaceuticals; Glucotrack and others jointly liable.
Pays $2.0M initial cash, issues $2.0M convertible note (5% interest, quarterly $500k payments from Nov 30, 2026 to Aug 31, 2027), plus up to $125k legal fees.
Note convertible into GCTK common at $2.98/share, subject to 9.99% beneficial ownership cap and Nasdaq limits.
Alto's release effective upon full payment; default triggers acceleration and increased interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.